- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Epix Medical gets public support
MRI contrast agent developer Epix Medical successfully launchedan initial public offering on Jan. 30, netting $13 million fromthe sale of 2 million shares. Initially offered at $7, the stockclosed at $8.75 on Feb. 12.The Cambridge, MA-based company's
MRI contrast agent developer Epix Medical successfully launchedan initial public offering on Jan. 30, netting $13 million fromthe sale of 2 million shares. Initially offered at $7, the stockclosed at $8.75 on Feb. 12.
The Cambridge, MA-based company's main product is MS-325, an MRIcontrast agent designed for the diagnosis of vascular diseases,including coronary artery disease and peripheral vascular disease(SCAN 12/18/96). Epix, formerly known as Metasyn, has formed strategicalliances to develop and commercialize MS-325 with contrast agentproducers Mallinckrodt and Daiichi.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
MRI-Based AI Model Shows Promise in Predicting Lymph Node Metastasis with Breast Cancer
April 15th 2024For the prediction of axillary lymph node metastasis in patients with breast cancer, an MRI-based, 4D convolutional neural network model demonstrated an AUC of 87 percent and sensitivity of 89 percent, according to new research.
